March 5, 2018 08:09 AM ESTUpdated 09:05 AM
R&D

Watch out be­low: Der­mi­ra ax­es ac­ne drug af­ter a cat­a­stroph­ic PhI­II fail­ure

John Carroll

Editor & Founder

Der­mi­ra set it­self up for one of the big stock $DERM cat­a­lysts of Q1 with its Phase III ac­ne stud­ies for DRM01. And it got …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times